Tildacerfont
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tildacerfont
- DrugBank Accession Number
- DB18545
- Background
Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 419.97
Monoisotopic: 419.1546594 - Chemical Formula
- C20H26ClN5OS
- Synonyms
- 3-(5-chloro-2-morpholin-4-yl-thiazol-4-yl)-7-(1-ethyl-propyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidine
- Pyrazolo(1,5-a)pyrimidine, 3-(4-chloro-2-(4-morpholinyl)-5-thiazolyl)-7-(1-ethylpropyl)-2,5-dimethyl-
- Pyrazolo(1,5-a)pyrimidine, 3-(4-chloro-2-(4-morpholinyl)-5-thiazolyl)-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo(1,3-a)pyrimidine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 09QCEV5481
- CAS number
- 1014983-00-6
- InChI Key
- CLKXPWDYEYIPFS-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)28-20(23-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3
- IUPAC Name
- 4-{5-chloro-4-[2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-thiazol-2-yl}morpholine
- SMILES
- CCC(CC)C1=CC(C)=NC2=C(C(C)=NN12)C1=C(Cl)SC(=N1)N1CCOCC1
References
- General References
- Not Available
- External Links
- ChemSpider
- 68006911
- ChEMBL
- CHEMBL5095198
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Polycystic Ovarian Syndrome (PCOS) 1 2 Recruiting Treatment 21-OHD / Congenital Adrenal Hyperplasia (CAH) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 4.93 Chemaxon pKa (Strongest Basic) 3.41 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 55.55 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 123.22 m3·mol-1 Chemaxon Polarizability 45.77 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at September 28, 2023 21:54 / Updated at September 29, 2023 14:17